Alternatives to Glutamine (Endari) If You Can't Fill Your Prescription

Glutamine (brand name Endari) is an FDA-approved treatment for sickle cell disease (SCD), but it's not always easy to access. Insurance denials, prior authorization delays, specialty pharmacy availability issues, and high costs can all prevent patients from getting it filled on time — or at all.

If you're facing one of those barriers, it's important to know your options. Several other FDA-approved medications treat sickle cell disease and can serve as alternatives or complements to Glutamine. Here's a clear comparison to help you have an informed conversation with your doctor.

Important: Always Talk to Your Doctor Before Switching

Sickle cell disease management is highly individualized. The right medication depends on your age, disease severity, other health conditions, and what you've tried before. Never stop or switch a medication without your doctor's guidance. This article is meant to help you ask the right questions — not to replace medical advice.

Alternative 1: Hydroxyurea (Droxia, Siklos, Hydrea)

Hydroxyurea is the most widely used and studied medication for sickle cell disease. It was approved by the FDA in 1998 — nearly 20 years before Glutamine — and remains the cornerstone of SCD treatment for most patients.

How it works: Hydroxyurea increases fetal hemoglobin (HbF) levels in the blood, which prevents the polymerization of hemoglobin S — the root cause of sickling. It also reduces the number of neutrophils and reticulocytes, lowering inflammation.

Who it's for: Adults and children with sickle cell anemia. Available as tablets or capsules taken once daily.

Compared to Glutamine: In fact, most insurance plans require patients to try hydroxyurea before approving Glutamine coverage. Many patients take both simultaneously — they have different mechanisms and can be complementary. Hydroxyurea is available as a lower-cost generic.

Key caution: Hydroxyurea can cause bone marrow suppression and should not be used during pregnancy. Regular blood count monitoring is required.

Alternative 2: Crizanlizumab (Adakveo)

Crizanlizumab (brand name Adakveo) was approved by the FDA in November 2019 for patients ages 16 and older to reduce the frequency of vaso-occlusive crises (VOCs) in sickle cell disease.

How it works: Crizanlizumab is a monoclonal antibody that blocks P-selectin, a protein involved in the adhesion of sickle cells to blood vessel walls. By preventing this adhesion, it reduces the vascular blockages that cause pain crises.

How it's given: IV infusion at a clinic or infusion center — once a month after an initial loading dose. This is very different from Glutamine's at-home oral powder format.

Compared to Glutamine: Crizanlizumab targets a different mechanism and is given by infusion rather than orally. It may be a good option for patients who struggle with the twice-daily powder regimen, or who cannot get Glutamine approved by insurance. Research suggests crizanlizumab may be more effective than Glutamine for reducing VOC frequency in some patients.

Alternative 3: Casgevy (Exa-Cel) — Gene Editing Therapy

Casgevy (exagamglogene autotemcel) was approved by the FDA in December 2023 as the world's first CRISPR-based gene editing therapy approved for any disease. It targets sickle cell anemia with the goal of providing a functional cure.

How it works: Casgevy modifies a patient's own stem cells to produce functional hemoglobin, effectively reducing or eliminating sickle cell crises. It is a one-time treatment.

Important context: Casgevy is not a medication you pick up at a pharmacy. It requires hospitalization, stem cell collection, conditioning chemotherapy, and is only available at specialized treatment centers. The cost is approximately $2.2 million. It is a very different type of intervention from Glutamine.

What About Voxelotor (Oxbryta)?

Voxelotor (Oxbryta) was FDA-approved in 2019 but was voluntarily withdrawn from the market by Pfizer in September 2024 due to safety concerns — specifically, a higher rate of VOC-related deaths was observed in a post-approval clinical trial. If you were previously taking Oxbryta, contact your hematologist about transitioning to another approved SCD treatment.

Comparison Table: Glutamine vs. Alternatives

Glutamine (Endari): Oral powder, twice daily, ages 5+, reduces VOCs by ~25%, at-home administration

Hydroxyurea: Oral tablet, once daily, all ages, reduces VOCs significantly, widely available generic, requires blood monitoring

Crizanlizumab: IV infusion monthly, ages 16+, reduces VOC frequency, clinic-based administration

Casgevy: One-time gene therapy, potentially curative, requires specialized treatment center, ~$2.2M cost

Can Glutamine Be Taken With Other SCD Medications?

Yes — and this is common. In the pivotal Phase 3 clinical trial for Endari, 63.4% of patients were already taking hydroxyurea and continued to do so throughout the study. Glutamine and hydroxyurea work through different mechanisms and can be safely combined. Talk to your hematologist about whether combination therapy makes sense for you.

If you're still trying to fill your Glutamine prescription, see our guide on how to find Glutamine in stock near you or explore savings options for Glutamine in 2026.